Trials in Progress
PIVOT-006: A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
- Condition:Bladder Cancer, Urothelial Carcinoma, Urologic Cancer, Non Muscle Invasive Bladder Cancer
- Study ID: NCT06111235
(UroToday.com) The 2024 American Society of Clinical Oncology Genitourinary (ASCO GU) cancers symposium held in San Francisco, CA between January 25th and 27th was host to a urothelial carcinoma trials in progress poster session. Dr. Robert Svatek presented the PIVOT-006 trial, a phase 3, randomized study of cretostimogene grenadenorepvec (CG) versus observation for the treatment of intermediate risk non-muscle invasive bladder cancer (NMIBC) following transurethral resection of bladder tumor (TURBT).Read More
(UroToday.com) The 2024 GU ASCO annual meeting featured a session on the shortage of drugs for urothelial carcinoma and a presentation by Dr. Josh Meeks discussing what is on the horizon to replace BCG. Dr. Meeks started his presentation with a case report of a 71 year old female who presented with gross hematuria and a CT scan showing a 3 cm bladder mass. A TURBT demonstrated T1 high grade urothelial carcinoma with CIS and with muscle in the specimen. A re-TURBT demonstrated only CIS. Dr. Meeks notes that in this situation the hospital has limited BCG available: there is an option to start BCG, but at only 1/3 the dose and you do not know if you can provide BCG through year 1. What do you recommend? Several options, which are all rational for this patient, include:Read More
Bladder cancer remains the sixth most commonly diagnosed cancer in the United States, with an estimated 82,290 incident cases in 2023.1 Because of the persistent recurrence risk of NMIBC in a highly comorbid population, there has been an FDA-led drive towards developing novel treatment options for these patients. The following article will highlight recent advances in this disease space with a specific focus on the oncolytic adenovirus agent cretostimogene grenadenorepvec, and the registration trial in intermediate risk non-muscle invasive bladder cancer (NMIBC), PIVOT-006.